Overall, the one-time LDCT diagnostic performance in the non-risk-based screening population had a sensitivity of 96.6%, a ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) ...

AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) for the use of its lung cancer treatments, Tagrisso (osimertinib ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer treatment, but data from a forthcoming study could quickly shake up the ...

A study aims to explore whether individuals eligible for lung cancer screening also access other preventive services.

The European Commission also approved AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy for adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence ...

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...